These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3144167)

  • 21. Treatment of supraventricular arrhythmias with encainide.
    Pool PE
    Am J Cardiol; 1986 Aug; 58(5):55C-57C. PubMed ID: 3092621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.
    Chimienti M; Moizi M; Salerno JA; Klersy C; Guasti L; Previtali M; Marangoni E; Montemartini C; Bobba P
    Eur Heart J; 1987 Mar; 8(3):282-90. PubMed ID: 3107987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acute therapy of tachycardic arrhythmias. 2: Supraventricular tachycardia--atrioventricular tachycardia (WPW syndrome)].
    Gonska BD; Rab J
    Fortschr Med; 1995 Mar; 113(7):87-9. PubMed ID: 7750890
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Electrophysiologic effects of penticainide in patients with supraventricular tachycardia].
    Kühlkamp V; Mewis C; Mayer F; Seipel L
    Z Kardiol; 1990 Oct; 79(10):725-31. PubMed ID: 2087860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome.
    Markel ML; Prystowsky EN; Heger JJ; Miles WM; Fineberg N; Zipes DP
    Am J Cardiol; 1986 Aug; 58(5):41C-48C. PubMed ID: 3092619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
    Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
    Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppressive effect of SUN1165 on supraventricular tachycardia.
    Terazawa T; Suzuki M; Goto T; Kato R; Hayashi H; Ito A; Isikawa S; Sotobata I
    Am Heart J; 1991 May; 121(5):1437-44. PubMed ID: 2017976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked Q-T prolongation due to encainide therapy.
    Davies W; Jazayeri M; Tchou P
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):283-6. PubMed ID: 3155328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of encainide in supraventricular arrhythmias.
    Pool PE
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():573-7. PubMed ID: 2125835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome.
    Manolis AS; Salem DN; Estes NA
    Am J Cardiol; 1989 Mar; 63(11):746-50. PubMed ID: 2493734
    [No Abstract]   [Full Text] [Related]  

  • 32. [Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation].
    Fauchier JP; Cosnay P; Moquet B; Rouesnel P; Kapusta P; Vrancea F
    Arch Mal Coeur Vaiss; 1986 Sep; 79(10):1506-14. PubMed ID: 3099684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of adenosine effects on atrioventricular node reentry and atrioventricular reciprocating tachycardias.
    Donahue JK; Orias D; Berger RD; Tomaselli GF; Lawrence JH; Calkins H
    Clin Cardiol; 1998 Oct; 21(10):743-5. PubMed ID: 9789695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug therapy of atrioventricular tachycardia].
    Seipel L; Kühlkamp V
    Ther Umsch; 1992 Aug; 49(8):536-42. PubMed ID: 1519182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of flecainide for supraventricular tachycardia.
    Neuss H; Schlepper M
    Am J Cardiol; 1988 Aug; 62(6):56D-61D. PubMed ID: 3136637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Electrophysiologic effects of betaxolol on conduction properties of the antegrade and retrograde pathway in patients with typical atrioventricular node reentry tachycardia following intravenous and oral administration].
    Kühlkamp V; Ickrath O; Haasis R; Seipel L
    Z Kardiol; 1988 Aug; 77(8):527-33. PubMed ID: 3176596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group.
    Darpö B; Edvardsson N
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):198-206. PubMed ID: 7475043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
    Manz M; Steinbeck G; Lüderitz B
    Am J Cardiol; 1985 Oct; 56(10):593-7. PubMed ID: 4050693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia.
    Gambhir DS; Bhargava M; Nair M; Arora R; Khalilullah M
    Indian Heart J; 1996; 48(2):133-7. PubMed ID: 8682552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.